Publications by authors named "Roser Calvo"

Claim this Profile
A
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Michael Wang, Tadeusz Robak, Kami J Maddocks, Tycel Phillips, Stephen D Smith, Roser Calvo

Blood Adv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy, Roser Calvo

Haematologica· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Paolo Strati, Morton Coleman, Rebecca Champion, Shuo Ma, Caterina Patti, Roser Calvo

Br J Haematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
Paul M Barr, Stephen D Smith, Mark J Roschewski, Susan M O'Brien, Jeff P Sharman, Roser Calvo

Leuk Lymphoma· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study.
Paolo Strati, Sven De Vos, Jia Ruan, Kami J Maddocks, Christopher R Flowers, Roser Calvo

Haematologica· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia.
Roser Calvo

Front Pharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are laboratory parameter (biomarker) values similar to the healthy volunteer reference range in all patient populations?
David A Brott, Michael J Goodman, Richard P Hermann, Michael Merz, Roser Calvo

Drug Des Devel Ther· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis